Cogent Biosciences Inc (COGT) - Total Assets
Based on the latest financial reports, Cogent Biosciences Inc (COGT) holds total assets worth $937.61 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cogent Biosciences Inc - Total Assets Trend (2015–2025)
This chart illustrates how Cogent Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Also see Cogent Biosciences Inc (COGT) market capitalisation for the company's overall valuation and market capitalisation.
Cogent Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cogent Biosciences Inc's total assets of $937.61 Million consist of 97.1% current assets and 2.9% non-current assets. Review how much debt does Cogent Biosciences Inc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Cogent Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Cogent Biosciences Inc (COGT) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cogent Biosciences Inc's current assets represent 97.1% of total assets in 2025, an increase from 96.1% in 2015.
- Cash Position: Cash and equivalents constituted 33.3% of total assets in 2025, down from 95.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Cogent Biosciences Inc Competitors by Total Assets
Key competitors of Cogent Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Cogent Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.23 | 5.32 | 28.16 |
| Quick Ratio | 14.23 | 5.32 | 28.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $846.40 Million | $240.76 Million | $223.83 Million |
Cogent Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Cogent Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.71 |
| Latest Market Cap to Assets Ratio | 5.67 |
| Asset Growth Rate (YoY) | 185.9% |
| Total Assets | $937.61 Million |
| Market Capitalization | $5.31 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Cogent Biosciences Inc's assets at a significant premium (5.67x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Cogent Biosciences Inc's assets grew by 185.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cogent Biosciences Inc (2015–2025)
The table below shows the annual total assets of Cogent Biosciences Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $937.61 Million | +185.94% |
| 2024-12-31 | $327.90 Million | +4.61% |
| 2023-12-31 | $313.44 Million | +4.20% |
| 2022-12-31 | $300.81 Million | +29.61% |
| 2021-12-31 | $232.09 Million | -7.50% |
| 2020-12-31 | $250.92 Million | +407.69% |
| 2019-12-31 | $49.42 Million | -42.48% |
| 2018-12-31 | $85.93 Million | +74.95% |
| 2017-12-31 | $49.12 Million | -34.99% |
| 2016-12-31 | $75.55 Million | -20.28% |
| 2015-12-31 | $94.77 Million | -- |
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more